Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Magenta Therapeutics Inc (MGTA)
NASDAQ:MGTA
Holding MGTA?
Track your performance easily
See the Price Targets and Ratings of:
MGTA Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MGTA Stock 12 Month Forecast
There Are No Analyst Ratings for MGTA In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
MGTA Financial Forecast
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
―
Hold
―
Reiterated
03/24/23
Magenta Therapeutics (MGTA) Receives a Hold from H.C. Wainwright
Wedbush
$1
Hold
42.94%
Upside
Downgraded
01/26/23
Wedbush Downgrades Magenta Therapeutics to Neutral
TD Cowen
―
Hold
―
Downgraded
01/26/23
Cowen Co. Downgrades Magenta Therapeutics to Market Perform
BTIG
―
Hold
―
Downgraded
01/26/23
Magenta Therapeutics downgraded to Neutral at BTIG after MGTA-117 trial pausedBTIG analyst Yun Zhong downgraded Magenta Therapeutics to Neutral from Buy with no price target after the company announced that the latest participant dosed at the Cohort 3 level in the ongoing MGTA -117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS, experienced a Grade 5 Serious Adverse Event. Magenta reported the death of the latest patient that received the Cohort 3 dose and the firm worries that the likelihood of an FDA approval for Magenta to evaluate MGTA-117 in transplant-eligible patients "has been significantly reduced" given that MGTA-117s toxicities "appear to be more serious that we expected."
MGTA Analyst Recommendation Trends
Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
MGTA Stock Forecast FAQ
What is MGTA’s average 12-month price target, according to analysts?
Currently, no data Available
What is MGTA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MGTA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MGTA a Buy, Sell or Hold?
Currently, no data Available
What is Magenta Therapeutics Inc’s price target?
Currently, no data Available
What do analysts say about Magenta Therapeutics Inc?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of MGTA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.